Table A2.
Outcome of Patients With a Positive Baseline Biomarker Signature
| Outcome | Placebo (n = 19) | Linifanib 7.5 mg (n = 24) | Linifanib 12.5 mg (n = 26) |
|---|---|---|---|
| PFS | |||
| Median, months | 5.4 | 10.2 | 8.3 |
| 95% CI, months | 1.5 to 6.9 | 3.9 to NR | 4.8 to NR |
| HR* | 0.49 | 0.38 | |
| P† | .049 | .029 | |
| OS | |||
| Median, months | 11.3 | 12.5 | 17.4 |
| 95% CI, months | 9.2 to 17.4 | 6.2 to NR | 12.9 to NR |
| HR* | 1.02 | 0.54 | |
| P† | .758 | .137 |
Abbreviations: HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.
*
Adjusted for Eastern Cooperative Oncology Group performance status and sex.
†
Stratified log-rank test; P value compared with placebo.